University of Bern

unibe.ch

Total trials

207

Active

60

Phase 3

4

Total enrollment

587,036

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Tirzepatide1
Stibium metallicum praeparatum 6x1
Epirubicin1
Mitomycin1
Gemcitabine1
Docetaxel1
Fluoxetine1
Sertraline Pill1
PRF as adjunct to non-surgical mechanical debridement1
Control, non-surgical mechanical debridement alone1
Regulated cannabis from authorized pharmacies1
Cannabis from the illicit market1
Cannabis1

Next readouts

  • 2026-06
  • 2026-06-19
  • 2026-09-30
  • 2026-10
  • 2026-12-24
  • 2027-12-28
  • 2028-08

Top conditions

  • Smoking Cessation12
  • Healthy9
  • Exposure to Man-made Visible Light7
  • Mild Cognitive Impairment7
  • Alzheimer Disease6
  • Schizophrenia and Related Disorders5
  • Childhood Cancer5
  • Suicidal Ideation5

Frequently asked questions about University of Bern

How many clinical trials does University of Bern have on ClinicalTrials.gov?
University of Bern is listed as the lead sponsor on 207 clinical trials in ClinicalTrials.gov, 60 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Bern's trials are in Phase 3?
4 of University of Bern's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does University of Bern focus on?
University of Bern's most-studied conditions on ClinicalTrials.gov are Smoking Cessation, Healthy, Exposure to Man-made Visible Light, Mild Cognitive Impairment, Alzheimer Disease.
When are University of Bern's next clinical trial readouts?
University of Bern has 7 upcoming primary-completion readouts tracked here; the soonest is “GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes”, expected around 2026-06.